Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis
Arthritis Care & Research , 07/24/2012
Kollert F et al. – Soluble CD90 (sCD90) concentrations were increased in systemic sclerosis (SSc) sera, particularly in patients with vascular involvement of the lung. These data suggests that sCD90 should be further evaluated as marker for diagnosis of pulmonary arterial hypertension (PAH) in SSc.Methods
- sCD90 serum concentrations were assessed in 76 patients with SSc and related to clinical data, lung function, six–minute walk distance, echocardiography, bronchoalveolar lavage fluid and laboratory parameters.
- Thirty–one healthy volunteers and 29 patients with idiopathic retroperitoneal fibrosis (IRF) served as controls.
- sCD90 serum concentrations were elevated in patients with SSc compared to healthy volunteers (p=0.001) and patients with IRF (p=0.01).
- SSc patients with pulmonary fibrosis (p=0.006) and in particular patients with PAH (p<0.001) had increased sCD90 serum concentrations compared to patients without the respective pulmonary manifestation of SSc.
- sCD90 levels correlated with diffusing capacity for carbon monoxide (n=65; r=–0.348; p=0.005) and systolic pulmonary arterial pressure (n=53; r=0.469; p<0.001).
- Receiver operating characteristics testing determined an optimal cut–off value of ≥626 ng/ml with a sensitivity of 68% and a specificity of 83% for PAH (area under the curve 0.773; 95% CI: 0.648–0.898; p<0.001).